佐力药业(300181) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the quarter was ¥302,761,394.08, representing a year-on-year growth of 32.64%[9] - Net profit attributable to shareholders was ¥31,663,476.71, a significant increase of 183.09% year-on-year[9] - The net profit after deducting non-recurring gains and losses was ¥30,421,221.64, up 217.02% compared to the same period last year[9] - Basic earnings per share for the quarter were ¥0.0520, an increase of 182.61% compared to the same period last year[9] - The total profit for the year-to-date period was 73.10 million yuan, an increase of 33.10 million yuan, with a year-on-year growth of 82.77%, primarily due to increased operating income[27] - The net profit for the year-to-date period was 66.03 million yuan, an increase of 30.00 million yuan, reflecting a year-on-year growth of 83.29% due to increased operating income[30] - The net profit for the current period was ¥24,553,774.76, significantly higher than ¥10,986,395.93 in the previous period, reflecting a growth of approximately 123.5%[71] - The total comprehensive income attributable to the parent company was ¥31,663,476.71, compared to ¥11,185,144.83 in the previous period, indicating a growth of approximately 183.5%[66] Cash Flow - Net cash flow from operating activities was ¥108,492,683.06, showing a remarkable increase of 2,657.95% year-on-year[9] - The net cash inflow from operating activities for the year-to-date period was 146.19 million yuan, an increase of 93.49 million yuan, representing a year-on-year growth of 177.39%, attributed to improved credit management and shorter collection periods[30] - Net cash flow from operating activities amounted to ¥146,188,796.32, significantly up from ¥52,702,076.31, indicating a year-over-year increase of 177.5%[91] - The parent company’s net cash flow from operating activities was ¥117,469,226.32, a significant improvement from -¥25,891,388.26 in the previous period[98] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,107,249,489.33, an increase of 2.76% compared to the previous year[9] - Current assets totaled ¥774,154,944.55, up from ¥690,910,086.08, indicating an increase of about 12.1% year-over-year[41] - Total liabilities were reported at ¥645,606,750.26, a marginal increase from ¥642,857,578.37, reflecting a growth of about 0.4%[49] - The company's short-term borrowings at the end of the reporting period were 302.82 million yuan, an increase of 86.00 million yuan, reflecting a growth of 39.67% due to changes in the financing structure[26] - The company's other payables at the end of the reporting period were 79.80 million yuan, an increase of 64.53 million yuan, representing a growth of 422.43%, mainly due to unpaid sales expenses and deposits[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 44,945[13] - The largest shareholder, Yu Youqiang, holds 28.46% of the shares, totaling 173,187,284 shares[13] Research and Development - Research and development expenses for the quarter were ¥6,265,661.80, compared to ¥5,809,660.12, indicating an increase of 7.8%[60] - Research and development expenses for the current period totaled ¥20,190,949.71, compared to ¥16,916,784.66 in the previous period, which is an increase of approximately 19.5%[74] - Research and development expenses amounted to ¥17,273,203.14, up from ¥14,269,997.09, indicating a growth of 14.0%[85] Financial Position - The company's equity attributable to shareholders increased to ¥1,360,551,249.00 from ¥1,310,354,170.19, showing a growth of about 3.8%[49] - The company's total assets decreased slightly to ¥1,773,054,226.02 from ¥1,782,240,474.66, a decline of 0.4%[57] - The company's equity increased to ¥1,352,069,158.03 from ¥1,317,502,587.64, reflecting a growth of 2.6%[57] Expenses - Total operating costs amounted to ¥275,977,525.80, up from ¥226,481,162.76, reflecting a rise of 21.8% year-over-year[60] - The company reported a significant increase in sales expenses, which rose to ¥153,908,465.36 from ¥114,822,210.07, an increase of 34.0%[60] - The company’s sales expenses increased to ¥388,251,923.88 from ¥319,226,100.34 in the previous period, representing a rise of approximately 21.6%[74] - The company incurred income tax expenses of ¥7,070,437.92, compared to ¥3,970,119.04 in the previous period, an increase of 78.5%[85] Investment Activities - Cash outflow from investment activities for the year-to-date period was 76.16 million yuan, an increase of 23.45 million yuan, reflecting a year-on-year increase of 44.48% due to net outflows from financial products[30] - Cash inflow from investment activities totaled ¥79,117,846.72, down from ¥97,274,217.37, representing a decrease of about 18.7%[94] - Cash outflow for investment activities was ¥155,273,618.37, slightly higher than ¥149,984,146.12 in the previous period, showing an increase of approximately 3.1%[94]